0HQK.LSE▲
Zacks highlights Eli Lilly, HSBC, Palantir, and CBL & Associates in latest analyst reports
Zacks Equity Research featured new reports on 16 major stocks, including Eli Lilly, HSBC, Palantir Technologies, and micro-cap CBL & Associates Properties. Eli Lilly shares have gained 58.2% over the past year, driven by strong demand for GLP-1 drugs Mounjaro and Zepbound, while its new oral obesity pill Foundayo is seen as a potential game-changer. HSBC shares rose 69.1%, supported by wealth momentum in Asia and the completed privatization of Hang Seng Bank, though higher expected credit losses and elevated expenses pose headwinds. Palantir shares declined 5.8% amid a broader industry drop of 18%, with its AI platforms driving government and commercial growth, but competition and no dividend remain concerns. CBL & Associates Properties, a micro-cap with a market capitalization of $1.63 billion, surged 119.3%, benefiting from stable operations and capital recycling, though modest organic growth and tenant turnover present risks.